Publication Author: Basu_Anirban
-
A sub-group evaluation of the multi-month dispensing strategy for differentiated HIV care: is personalization of care guidelines warranted in Haiti?
Parrish C, Basu A, Fishman P, Koama JB, Robin E, Francois K, Honoré JG, Van Onacker JD, Puttkammer N. A sub-group evaluation of the multi-month dispensing strategy for differentiated HIV care: is personalization of care guidelines warranted in Haiti? BMC
rakerr2
-
The post COVID-19 healthcare landscape and the use of long-acting injectable antipsychotics for individuals with schizophrenia and bipolar I disorder: the importance of an integrated collaborative-care approach.
Correll CU, Chepke C, Gionfriddo P, Parks J, Foxworth P, Basu A, Brister TS, Brown D, Clarke C, Hassoun Y. The post COVID-19 healthcare landscape and the use of long-acting injectable antipsychotics for individuals with schizophrenia and bipolar I disorde
rakerr2
-
Minimum Threshold of Bariatric Surgical Weight Loss for Initial Diabetes Remission.
Barthold D, Brouwer E, Barton LJ, Arterburn DE, Basu A, Courcoulas A, Crawford CL, Fedorka PN, Fischer H, Kim BB, Mun EC, Murali SB, Reynolds K, Yoon TK, Zane RE, Coleman KJ. Minimum Threshold of Bariatric Surgical Weight Loss for Initial Diabetes Remissi
rakerr2
-
Exploring Providers’ Perception to Naloxone Education for Opioid Overdose After Receiving Academic Detailing at the U.S. Department of Veterans Affairs.
Bounthavong M, Christopher MLD, Veenstra DL, Basu A, Devine EB. Exploring Providers’ Perception to Naloxone Education for Opioid Overdose After Receiving Academic Detailing at the U.S. Department of Veterans Affairs. J Pharm Pract. 2021 Nov 12:89719002110
rakerr2
-
A Value-of-Information Framework for Personalizing the Timing of Surveillance Testing.
Bansal A, Heagerty PJ, Inoue LYT, Veenstra DL, Wolock CJ, Basu A. A Value-of-Information Framework for Personalizing the Timing of Surveillance Testing. Med Decis Making. 2022 May;42(4):474-486. doi: 10.1177/0272989X211049213. Epub 2021 Nov 7.
rakerr2
-
Do Cost-Effectiveness Analyses Account for Drug Genericization? A Literature Review and Assessment of Implications.
Neumann PJ, Podolsky MI, Basu A, Ollendorf DA, Cohen JT. Do Cost-Effectiveness Analyses Account for Drug Genericization? A Literature Review and Assessment of Implications. Value Health. 2022 Jan;25(1):59-68. doi: 10.1016/j.jval.2021.06.014. Epub 2021 Nov
rakerr2
-
Protocol for an observational cohort study investigating personalised medicine for intensification of treatment in people with type 2 diabetes mellitus: the PERMIT study.
Bidulka P, O’Neill S, Basu A, Wilkinson S, Silverwood RJ, Charlton P, Briggs A, Adler AI, Khunti K, Tomlinson LA, Smeeth L, Douglas IJ, Grieve R. Protocol for an observational cohort study investigating personalised medicine for intensification of treatme
rakerr2
-
The Use of Cost-Effectiveness Analysis in Sickle Cell Disease: A Critical Review of the Literature.
Jiao B, Basu A, Roth J, Bender M, Rovira I, Clemons T, Quach D, Ramsey S, Devine B. The Use of Cost-Effectiveness Analysis in Sickle Cell Disease: A Critical Review of the Literature. Pharmacoeconomics. 2021 Nov;39(11):1225-1241. doi: 10.1007/s40273-021-0
rakerr2
-
Estimating the effect of increasing dispensing intervals on retention in care for people with HIV in Haiti.
Parrish C, Basu A, Fishman P, Koama JB, Robin E, Francois K, Honoré JG, Van Onacker JD, Puttkammer N. Estimating the effect of increasing dispensing intervals on retention in care for people with HIV in Haiti. EClinicalMedicine. 2021 Jul 23;38:101039. doi
rakerr2
-
How Does Cost-Effectiveness Analysis Inform Health Care Decisions?
Kim DD, Basu A. How Does Cost-Effectiveness Analysis Inform Health Care Decisions? AMA J Ethics. 2021 Aug 1;23(8):E639-647. doi: 10.1001/amajethics.2021.639.
rakerr2